NuVasive Replaces CFO In Wake Of Poor Q2
Spine firm NuVasive has named Rajesh Asarpota as the company's new executive vice president and chief financial officer. He steps in after the previous CFO left following NuVasive's disappointing Q2 2017 results.
You may also be interested in...
With earnings reporting season now in full swing, Medtech Insight highlights which companies have exceeded expectations and which ones continue to see their bottom-line sink. This edition throws the spotlight on some of the notable players in the orthopedics space.
Just nine months after spinning out from Covidien, Mallinckrodt is maintaining its ambition to grow its speciality pharma business aggressively with the planned $5.6bn merger with Questcor Pharmaceuticals. The announcement came only weeks after Mallinckrodt closed its $1.3bn acquisition of Cadence Pharmaceuticals (www.scripintelligence.com, 12 February 2014) and continues to fulfil the commitment Mark Trudeau, Mallinckrodt’s president and CEO, made to investors and analysts last fall.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.